Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma.

Jason A MouabbiWei QaioYu ShenAkshara Singareeka RaghavendraDebasish TripathyRachel M Layman

Published in: The oncologist (2023)

In ET-refractory HR+ HER2-negative mILC, single-agent CAP demonstrated superior PFS compared to TAX. Our findings highlight the potential benefit of CAP in this patient subset, warranting further investigation through prospective trials.

Keyphrases

squamous cell carcinoma
small cell lung cancer
locally advanced
stem cells
radiation therapy
risk assessment
human health
rectal cancer
replacement therapy